• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IDT
Click for more information
0.00% 10.0¢

IDT AUSTRALIA LIMITED - Announcements

Market Cap $51.58M  ! watchlist Created with Sketch. Add to my watchlist

IDT Australia Limited is a pharmaceutical manufacturing company. The Company is engaged... IDT Australia Limited is a pharmaceutical manufacturing company. The Company is engaged in the supply of products and provision of research and development and other technical services within the pharmaceutical and allied industries. Its business includes research and development, active pharmaceutical ingredient (API) and finished dosage form manufacture (FDF), clinical and commercial, project management, chemical services, analytical chemistry, pharmacy services, pharmaceutical development in all dosage forms, clinical packaging and regulatory affairs services. Its Current Good Manufacturing Practice (cGMP) manufacturing facilities produces both API and FDF across the medicinal cannabis manufacturing space. It also provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms. Its analytical laboratories offer medicinal cannabis cGMP testing.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
IDT Appendix 4EPRICE SENSITIVE23/08/17
IDT Updated Charter Remuneration and Nomination Committee23/08/17
IDT Updated Charter Audit and Risk Committee23/08/17
IDT Resignation of Managing DirectorPRICE SENSITIVE14/07/17
IDT Cancellation Shares and Options13/06/17
IDT Director Retirement - Graeme BlackmanPRICE SENSITIVE13/06/17
IDT Appendix 3Z - Graeme Blackman13/06/17
IDT Corporate Governance Statement09/06/17
IDT Receives Victorian Manufacturing Hall of Fame Award10/05/17
IDT US launch of PindololPRICE SENSITIVE09/05/17
IDT FDA review clears Pindolol for US launchPRICE SENSITIVE27/04/17
IDT Appendix 3Z26/04/17
IDT Appendix 3Y12/04/17
IDT Generics Sales UpdatePRICE SENSITIVE12/04/17
IDT Appendix 3Y28/03/17
IDT Appendix 3X01/03/17
IDT Director Appointment - Mary Sontrop01/03/17
IDT Cancellation of Shares23/02/17
IDT Half Yearly Report and Accounts21/02/17
IDT Appendix 4DPRICE SENSITIVE21/02/17
IDT Change in substantial holding03/01/17
IDT Becoming a substantial holder03/01/17
IDT Change in substantial holding21/12/16
IDT Completion of Initial CMAX TransactionPRICE SENSITIVE15/12/16
IDT Mayne Pharma Announces U.S. Launch of IDT's TemozolomidePRICE SENSITIVE22/11/16
IDT Ceasing to be a substantial holder from AEF07/11/16
IDT 1st generic proprietary product shipped to US, temozolomide,MYX-IDT.AX PRICE SENSITIVE02/11/16
IDT IDT Divests CMAX Clinical Trial Business to I'rom Group-IDT.AX PRICE SENSITIVE28/10/16
IDT Trading halt-IDT.AX PRICE SENSITIVE26/10/16
IDT Appendix 3B-IDT.AX 21/10/16
IDT Results of Meeting-IDT.AX 18/10/16
IDT Director Resignation-IDT.AX 18/10/16
IDT Investor Presentation, AGM 17 October 2016-IDT.AX 17/10/16
IDT Receives Export Award, Health and Biotechnology-IDT.AX 07/10/16
IDT Change in substantial holder from AEF,AEF-IDT.AX 30/09/16
IDT Change in substantial holder from AEF,AEF-IDT.AX 30/09/16
IDT Cancellation of shares-IDT.AX 21/09/16
IDT Appendix 3B-IDT.AX 21/09/16
IDT Notice of Annual General Meeting/Proxy Form-IDT.AX 16/09/16
IDT Awarded Future Industries Manufacturing Program Grant-IDT.AX PRICE SENSITIVE06/09/16
IDT Appendix 4G-IDT.AX 28/08/16
IDT Appendix 4G-IDT.AX 25/08/16
IDT Full Year Statutory Accounts-IDT.AX 24/08/16
IDT Appendix 4E-IDT.AX PRICE SENSITIVE24/08/16
IDT Appendix 3B-IDT.AX 03/08/16
IDT Cleansing Notice-IDT.AX 06/07/16
IDT Appendix 3B-IDT.AX 06/07/16
IDT Becoming a substantial holder-IDT.AX 01/07/16
IDT Completion of private placement-IDT.AX PRICE SENSITIVE30/06/16
IDT Trading Halt-IDT.AX PRICE SENSITIVE28/06/16
IDT Updated Investor Presentation-IDT.AX 27/06/16
IDT Ceasing to be a substantial holder-IDT.AX 08/06/16
IDT CMAX - Opening of new Clinical Trial Facility-IDT.AX PRICE SENSITIVE02/05/16
IDT Updated Investor Presentation-IDT.AX 14/04/16
IDT FDA Approval for Temozolomide-IDT.AX PRICE SENSITIVE13/04/16
IDT Manufacturing partner appointedPRICE SENSITIVE30/03/16
IDT Thiotepa - Contract Extension and RevenuesPRICE SENSITIVE09/03/16
IDT Half Yearly Report and Accounts19/02/16
IDT Appendix 4DPRICE SENSITIVE19/02/16
IDT Ceasing to be a substantial holder15/02/16
IDT Becoming a substantial holder05/01/16
IDT Cleansing Notice23/12/15
IDT Appendix 3B23/12/15
IDT Share Purchase Plan Finalisation23/12/15
IDT SPP Closed16/12/15
IDT Cancellation of Shares10/12/15
IDT Appendix 3Y30/11/15
IDT Becoming a substantial holder26/11/15
IDT Cleansing Notice25/11/15
IDT Appendix 3B25/11/15
IDT Share Purchase Plan - Offer Document23/11/15
IDT Share Purchase Plan - Overview23/11/15
IDT Cleansing Notice23/11/15
IDT Appendix 3B20/11/15
IDT Results of Meeting19/11/15
IDT $6m Placement to Accelerate IDT's Generic Drug PortfolioPRICE SENSITIVE19/11/15
IDT AGM Presentation19/11/15
IDT Ceasing to be a substantial holder19/11/15
IDT Amendment - Ceasing to be a substantial holder.17/11/15
IDT Trading HaltPRICE SENSITIVE17/11/15
IDT Ceasing to be a substantial holder17/11/15
IDT Change in substantial holding from AEF05/11/15
IDT Notice of Annual General Meeting/Proxy Form08/10/15
IDT Appendix 3X08/10/15
IDT Director Appointment08/10/15
IDT IDT Executes US Distribution Agreement for TemozolomidePRICE SENSITIVE24/09/15
IDT Change in substantial holding from AEF21/08/15
IDT Appendix 4G18/08/15
IDT FY15 Results Announcement18/08/15
IDT Full Year Statutory Accounts18/08/15
IDT Appendix 4EPRICE SENSITIVE18/08/15
IDT Appointment US Distributor for Generic PortfolioPRICE SENSITIVE12/08/15
IDT Cleansing Notice24/07/15
IDT Appendix 3B21/07/15
IDT BioShares Conference Presentation20/07/15
IDT Becoming a substantial holder29/06/15
IDT New Director appointment and accompanying App3X10/06/15
IDT Updated Investor Presentation01/06/15
IDT Updated Security Trading Policy20/05/15
IDT Director Resignation19/05/15
IDT Appendix 4E
23/08/17PRICE SENSITIVE
IDT Updated Charter Remuneration and Nomination Committee
23/08/17
IDT Updated Charter Audit and Risk Committee
23/08/17
IDT Resignation of Managing Director
14/07/17PRICE SENSITIVE
IDT Cancellation Shares and Options
13/06/17
IDT Director Retirement - Graeme Blackman
13/06/17PRICE SENSITIVE
IDT Appendix 3Z - Graeme Blackman
13/06/17
IDT Corporate Governance Statement
09/06/17
IDT Receives Victorian Manufacturing Hall of Fame Award
10/05/17
IDT US launch of Pindolol
09/05/17PRICE SENSITIVE
IDT FDA review clears Pindolol for US launch
27/04/17PRICE SENSITIVE
IDT Appendix 3Z
26/04/17
IDT Appendix 3Y
12/04/17
IDT Generics Sales Update
12/04/17PRICE SENSITIVE
IDT Appendix 3Y
28/03/17
IDT Appendix 3X
01/03/17
IDT Director Appointment - Mary Sontrop
01/03/17
IDT Cancellation of Shares
23/02/17
IDT Half Yearly Report and Accounts
21/02/17
IDT Appendix 4D
21/02/17PRICE SENSITIVE
IDT Change in substantial holding
03/01/17
IDT Becoming a substantial holder
03/01/17
IDT Change in substantial holding
21/12/16
IDT Completion of Initial CMAX Transaction
15/12/16PRICE SENSITIVE
IDT Mayne Pharma Announces U.S. Launch of IDT's Temozolomide
22/11/16PRICE SENSITIVE
IDT Ceasing to be a substantial holder from AEF
07/11/16
IDT 1st generic proprietary product shipped to US, temozolomide,MYX-IDT.AX
02/11/16PRICE SENSITIVE
IDT IDT Divests CMAX Clinical Trial Business to I'rom Group-IDT.AX
28/10/16PRICE SENSITIVE
IDT Trading halt-IDT.AX
26/10/16PRICE SENSITIVE
IDT Appendix 3B-IDT.AX
21/10/16
IDT Results of Meeting-IDT.AX
18/10/16
IDT Director Resignation-IDT.AX
18/10/16
IDT Investor Presentation, AGM 17 October 2016-IDT.AX
17/10/16
IDT Receives Export Award, Health and Biotechnology-IDT.AX
07/10/16
IDT Change in substantial holder from AEF,AEF-IDT.AX
30/09/16
IDT Change in substantial holder from AEF,AEF-IDT.AX
30/09/16
IDT Cancellation of shares-IDT.AX
21/09/16
IDT Appendix 3B-IDT.AX
21/09/16
IDT Notice of Annual General Meeting/Proxy Form-IDT.AX
16/09/16
IDT Awarded Future Industries Manufacturing Program Grant-IDT.AX
06/09/16PRICE SENSITIVE
IDT Appendix 4G-IDT.AX
28/08/16
IDT Appendix 4G-IDT.AX
25/08/16
IDT Full Year Statutory Accounts-IDT.AX
24/08/16
IDT Appendix 4E-IDT.AX
24/08/16PRICE SENSITIVE
IDT Appendix 3B-IDT.AX
03/08/16
IDT Cleansing Notice-IDT.AX
06/07/16
IDT Appendix 3B-IDT.AX
06/07/16
IDT Becoming a substantial holder-IDT.AX
01/07/16
IDT Completion of private placement-IDT.AX
30/06/16PRICE SENSITIVE
IDT Trading Halt-IDT.AX
28/06/16PRICE SENSITIVE
IDT Updated Investor Presentation-IDT.AX
27/06/16
IDT Ceasing to be a substantial holder-IDT.AX
08/06/16
IDT CMAX - Opening of new Clinical Trial Facility-IDT.AX
02/05/16PRICE SENSITIVE
IDT Updated Investor Presentation-IDT.AX
14/04/16
IDT FDA Approval for Temozolomide-IDT.AX
13/04/16PRICE SENSITIVE
IDT Manufacturing partner appointed
30/03/16PRICE SENSITIVE
IDT Thiotepa - Contract Extension and Revenues
09/03/16PRICE SENSITIVE
IDT Half Yearly Report and Accounts
19/02/16
IDT Appendix 4D
19/02/16PRICE SENSITIVE
IDT Ceasing to be a substantial holder
15/02/16
IDT Becoming a substantial holder
05/01/16
IDT Cleansing Notice
23/12/15
IDT Appendix 3B
23/12/15
IDT Share Purchase Plan Finalisation
23/12/15
IDT SPP Closed
16/12/15
IDT Cancellation of Shares
10/12/15
IDT Appendix 3Y
30/11/15
IDT Becoming a substantial holder
26/11/15
IDT Cleansing Notice
25/11/15
IDT Appendix 3B
25/11/15
IDT Share Purchase Plan - Offer Document
23/11/15
IDT Share Purchase Plan - Overview
23/11/15
IDT Cleansing Notice
23/11/15
IDT Appendix 3B
20/11/15
IDT Results of Meeting
19/11/15
IDT $6m Placement to Accelerate IDT's Generic Drug Portfolio
19/11/15PRICE SENSITIVE
IDT AGM Presentation
19/11/15
IDT Ceasing to be a substantial holder
19/11/15
IDT Amendment - Ceasing to be a substantial holder.
17/11/15
IDT Trading Halt
17/11/15PRICE SENSITIVE
IDT Ceasing to be a substantial holder
17/11/15
IDT Change in substantial holding from AEF
05/11/15
IDT Notice of Annual General Meeting/Proxy Form
08/10/15
IDT Appendix 3X
08/10/15
IDT Director Appointment
08/10/15
IDT IDT Executes US Distribution Agreement for Temozolomide
24/09/15PRICE SENSITIVE
IDT Change in substantial holding from AEF
21/08/15
IDT Appendix 4G
18/08/15
IDT FY15 Results Announcement
18/08/15
IDT Full Year Statutory Accounts
18/08/15
IDT Appendix 4E
18/08/15PRICE SENSITIVE
IDT Appointment US Distributor for Generic Portfolio
12/08/15PRICE SENSITIVE
IDT Cleansing Notice
24/07/15
IDT Appendix 3B
21/07/15
IDT BioShares Conference Presentation
20/07/15
IDT Becoming a substantial holder
29/06/15
IDT New Director appointment and accompanying App3X
10/06/15
IDT Updated Investor Presentation
01/06/15
IDT Updated Security Trading Policy
20/05/15
IDT Director Resignation
19/05/15
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
10.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $51.58M
Open High Low Value Volume
10.5¢ 10.5¢ 10.0¢ $32.47K 324.4K

Buyers (Bids)

No. Vol. Price($)
3 235534 10.0¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 114593 3
View Market Depth
Last trade - 15.59pm 22/11/2024 (20 minute delay) ?
Last
10.0¢ 		  Change
0.000 ( 0.00 %)
Open High Low Volume
10.0¢ 10.0¢ 10.0¢ 26414
Last updated 15.51pm 22/11/2024 ?
IDT (ASX) Chart

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
HotCopper Highlights: Your most watched stocks for Week 47, 2024 In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing, through Week 47. Let’s get into it. 
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL Welcome to the end of another week. Let's start with what HotCopper users have been watching and discussing.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.